绩後获瑞信唱好石药(01093.HK)续涨8%获哮喘靶向治疗药内地授权
中期业绩多赚25%兼获瑞信上调评级至「跑赢大市」的石药集团(01093.HK)今早股价受追捧,公司附属亦与兴盟生物开展合作哮喘药,该股今早升破百天线(13.48元),最高见14.16元,逼近牛熊线(14.52元),现造13.98元,续涨7.9%为最强蓝筹,成交已达3,247万股,涉资4.47亿元。
石药公布,全资附属石药百克与兴盟生物医药订立协议,获对方授出已於03年获准在美国上市的全球首只哮喘靶向治疗药物--奥马珠单抗生物类似药(SYN008)内地独家权利,以便其在内地进行该产品有关的所有适应症开发与商业化,该产品已於澳洲完成生物等效研究,并预期短期内在中国申请开展III期临床试验。而相关代价则为石药百克同意向兴盟支付1,000万人民币首付款及根据该产品於该地区开发进度支付最多5,000万人民币之开发里程碑付款,并会根据该产品於该地区达成之销售额向兴盟支付销售提成。
石药昨午公布,上半年纯利按年升25%至18.78亿元人民币(下同),每股盈利30.13分,维持不派中期息。期内,总收入按年增近28%至111.78亿元;毛利按年增近40%至78.13亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.